PD967 - USING BODY MASS INDEX AND SARCOPENIA RISK ASSESSMENT: COMPARISON OF FRAILTY, DEPENDENCE AND INFLAMMATION IN GERIATRIC INPATIENTS WITH OBESITY, SARCOPENIA RISK AND POTENTIAL SARCOPENIC OBESITY
PD967
USING BODY MASS INDEX AND SARCOPENIA RISK ASSESSMENT: COMPARISON OF FRAILTY, DEPENDENCE AND INFLAMMATION IN GERIATRIC INPATIENTS WITH OBESITY, SARCOPENIA RISK AND POTENTIAL SARCOPENIC OBESITY
C. O. Walowski1,*, C. Herpich1,2,3, U. Müller-Werdan2,4, K. Norman1,2,3,5
1Department of Nutrition and Gerontology, German Institute of Human Nutrition , Potsdam-Rehbrücke, 2Department of Geriatrics and Medical Gerontology, Charité-Universitätsmedizin , Berlin, 3Institute of Nutritional Science, University of Potsdam, Potsdam, 4Protestant Geriatric Center Berlin gGmbH, Berlin, 5German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany
Rationale: Advanced body composition measurements are often not available in routine clinical practice. We therefore investigated the prevalence of probable sarcopenic obesity (SO) using body mass index (BMI) and the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F) questionnaire, and the association on functional capacity and inflammatory markers in geriatric patients aged ≥60 years.
Methods: In this cross-sectional analysis, inpatients (n=250) were classified into three groups based on sarcopenia risk (SARC-F) and BMI (kg/m²): probable clinical obesity (BMI ≥30, SARC-F <4), probable sarcopenia (SARC-F ≥4, BMI <30) and probable SO (SARC-F ≥4, BMI ≥30). Frailty phenotype was evaluated according to Fried criteria and functional capacity by the Barthel Index of activities of daily living (ADL). Serum growth differentiation factor-15 (GDF15), interleukin (IL) 6 and IL10 were quantified. One-way ANOVA and Kruskal-Wallis test were used as appropriate.
Results: The prevalence of probable clinical obesity, sarcopenia and SO were 6%, 74% and 20%, respectively. Frailty prevalence was highest with SO (72.0%) compared to those with sarcopenia and obesity alone (66.5%; 20.0%; p=0.001). ADL scores were lower in SO (50 [45;65]) than in obesity (70 [45;95]) and sarcopenia (65 [50;80]; p=0.015). The proportion of patients requiring substantial care was highest in SO (87.8%) vs obesity (71.4%) and sarcopenia (61.1%; p=0.007). IL10 was highest in SO (13.4 [10.5;18.7] pg/mL; p=0.004), whereas IL6 and GDF15 did not differ.
Conclusion: In geriatric inpatients, screening-defined probable SO is associated with higher frailty and dependence rates and higher IL10 concentrations compared with BMI-defined obesity or SARC-F positive sarcopenia risk alone, suggesting synergistic effects on adverse outcomes.
Disclosure of Interest: None declared